CNS Penetration Ability: A Critical Factor for Drugs in the Treatment of SARS-CoV-2 Brain Infection | Zendy

Chhanda Charan Danta | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

CNS Penetration Ability: A Critical Factor for Drugs in the Treatment of SARS-CoV-2 Brain Infection

Author(s) -

Chhanda Charan Danta

Publication year - 2020

Publication title -

acs chemical neuroscience

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.158

H-Index - 69

ISSN - 1948-7193

DOI - 10.1021/acschemneuro.0c00335

Subject(s) - blood–brain barrier , covid-19 , medicine , drug , penetration (warfare) , virology , virus , central nervous system , pharmacology , infectious disease (medical specialty) , disease , operations research , engineering

Now, it has been evidenced that Covid19 (SARS-CoV-2) infects the brain tissues. Along with this, a challenge has been raised for research professionals to find effective drugs for its treatment since the recent spread of this virus from Wuhan, China. Targeting the treatment of brain infection, it has also been a challenge that the clinical drug should have good CNS penetration ability to cross the blood-brain barrier.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research